<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186875</url>
  </required_header>
  <id_info>
    <org_study_id>ALLR17</org_study_id>
    <secondary_id>NCI-2011-01256</secondary_id>
    <nct_id>NCT00186875</nct_id>
  </id_info>
  <brief_title>Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to find out how well participants with relapsed or
      refractory ALL respond to treatment with an etoposide- and teniposide-based induction
      chemotherapy regimen and what the side effects are.

      Primary Objectives:

        -  To estimate the response rate for patients with refractory or relapsed ALL.

        -  To estimate the survival rate of patients with refractory or relapsed ALL treated with
           risk-directed therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will be divided into high-risk and standard-risk subgroups according
      to the length of their first remission, the type of early cancer cell (T or B-cell) and the
      site or sites of disease relapse. The remission induction phase (the beginning phase of
      therapy) will consist of three blocks of therapy. Block A features daily IV low-dose
      etoposide in combination with cytarabine given by continuous IV, weekly vincristine, and
      daily dexamethasone. In block B, a combination of weekly PEG-asparaginase, vincristine, and
      daily dexamethasone will be given. Block C will be a combination of high-dose methotrexate,
      high-dose cytarabine, and teniposide.

      There will be two phases of consolidation (treatment phase after induction therapy).
      Additional therapy will be given between the two consolidation phases. Continuation will
      consist of eight weekly cycles of chemotherapy. Periodic intrathecal therapy (medicine given
      into the spinal fluid) will be given throughout the treatment. Participants who do not
      achieve remission (absence of leukemia) after consolidation will be offered enrollment on St.
      Jude NKEHM protocol (NK cell transplant). Hematopoietic stem cell transplant (HSCT) is
      planned for participants with high risk disease. HSCT will be done according to current
      institutional practice. The duration of chemotherapy will be one year for patients with
      extramedullary (outside the bone marrow) relapse and two years for all others.

      Exploratory objectives include:

        -  To determine the prevalence of MRD in children undergoing treatment for relapsed ALL and
           to compare the results to those obtained in children with newly diagnosed ALL.

        -  To compare the level of MRD in bone marrow and peripheral blood concomitantly in
           children undergoing treatment for relapsed ALL.

        -  To characterize the gene expression profile of leukemia cells at the time of diagnosis
           and relapse to improve our understanding of mechanisms of relapse and of the development
           of drug resistance.

        -  To study whether pre-existing or emerging development of serum antibodies to
           asparaginase is related to hypersensitivity reaction to asparaginase in patient with
           relapsed ALL.

      Detailed Description of Treatment Plan:

      All patients will receive the same remission induction. All high-risk patients will be
      offered HSCT which will be performed after a suitable donor is identified and preferably
      after MRD becomes negative. If they do not have a donor or they refuse HSCT, they will
      continue to receive chemotherapy. Standard-risk patients continue chemotherapy if MRD is
      negative after induction, but will be offered HSCT if MRD is &gt;0.01% after Block C of
      Induction. Those who do not achieve morphological CR after induction will be treated
      according to the contingency plan.

      Block A (14 days)

      Dexamethasone 5 mg/m2/day, days 1-14

      Vincristine 1.5 mg/m2 (max 2 mg), days 1 and 8

      Etoposide 25 mg/m2, days 1-14

      Cytarabine 25 mg/m2, days 1-14

      All patients will proceed to Block B if the clinical condition permits.

      CNS prophylaxis (IT MHA)

      CNS-1: At the time of relapse and day 14.

      CNS-2 and 3: At the time of relapse, day 8 and 14.

      Leucovorin: 5 mg/m2 (5 mg max dose) PO, 24 and 30 hours after each IT MHA.

      Block B (15 days)

      All patients will proceed to Block B immediately after Block A if they are clinically well.

      Dexamethasone 6 mg/m2, Days 1-14

      Vincristine 1.5 mg/m2, days 1 and 8

      PEG-Asparaginase 2500 units/m2, days 1, 8 and 15

      CNS prophylaxis (IT MHA): CNS-2 or 3 only, if necessary.

        -  CNS-1: no IT MHA

        -  CNS-2 and 3: day 8 (minimum 4 doses and maximum 8 doses during induction)

      Leucovorin: 5 mg/m2 (5 mg max) PO 24 and 30 hours after each IT MHA

      Block C (1 day)

      All patients who received Block B will proceed to Block C when WBC &gt;1,000/microL, ANC
      &gt;300/microL and platelets &gt;50,000 microL after recovery from Block B.

      Methotrexate 8 gm/m2, day 1

      Cytarabine 1 g/m2 at least 24 h after ITHMA, day 1

      Teniposide 165 mg/m2, day 1

      CNS prophylaxis (IT MHA):

        -  CNS-1: at the time of BMA after Block C

        -  CNS-2 and 3: day 1 and 8 (These two doses of IT MHA may be omitted if the patient had
           negative CSF for blasts in the 3 preceding CSF exam) and at the time of BMA after Block
           C (regardless of the previous CSF status).

      Leucovorin: 5 mg/m2 (5 mg maximum dose) PO 24 and 30 hours after each IT MHA

      Consolidation I

      This is a 4-week phase. It will be started if WBC &gt;1000/microL, ANC &gt;500/microL and platelets
      &gt;50,000 /microL

      Week 1: Dex day 1, 2, 3, PEG, VCR, Mito day 4

      Week 2: Dex day 1, 2, 3, PEG, VCR, day 4

      Week 3: Dex day 1, 2, 3, PEG, VCR, Mito day 4

      Week 4: Dex day 1, 2, 3, PEG, VCR, day 4

      Dexamethasone 8 mg/m2/day, day 1-3

      PEG-Asparaginase 2500 units/m2 IM, day 4 each week

      Vincristine 2 mg/m2 (max 2 mg), day 4 each week

      Mitoxantrone 12 mg/m2, day 4 week 1 and 3

      Interim Continuation

      Week 1*†:

      etoposide 300 mg/m2 IV, 1 dose on day 1

      Cyclophosphamide 300 mg/m2 IV, 1 dose on day 1

      Week 2*:

      Methotrexate 40 mg/m2 IV, 1 dose on day 1

      6-mercaptopurine# 75 mg/m2 PO, Days 1 to 7

      Week 3*:

      teniposide 150 mg/m2 IV, 1 dose on day 1

      Cytarabine 300 mg/m2 IV, 1 dose on day 1

      Week 4*:

      Dexamethasone§ 12 mg/m2/day PO, TID Days 1 to 5

      Vinblastine 6 mg/m2 IV (max 10 mg), 1 dose on day 1

      Consolidation II

      Week 1*†:

      etoposide 300 mg/m2 IV, 1 dose on day 1

      Cyclophosphamide 300 mg/m2 IV, 1 dose on day 1

      Week 2*:

      Methotrexate 40 mg/m2 IV, 1 dose on day 1

      6-mercaptopurine# 75 mg/m2 PO, Days 1 to 7

      Week 3*:

      teniposide 150 mg/m2 IV, 1 dose on day 1

      Cytarabine 300 mg/m2 IV, 1 dose on day 1

      Week 4*:

      Dexamethasone§ 12 mg/m2/day PO, TID, Days 1 to 5

      Vinblastine 6 mg/m2 IV (max 10 mg), 1 dose on day 1

      Continuation

      Week 1*†¶:

      etoposide 300 mg/m2 IV, 1 dose on day 1

      Cyclophosphamide 300 mg/m2 IV, 1 dose on day 1

      Week 2*:

      Methotrexate 40 mg/m2 IV, 1 dose on day 1

      6-mercaptopurine# 75 mg/m2 PO, QHS, Days 1 to 7

      Week 3*:

      teniposide 150 mg/m2 IV, 1 dose on day 1

      Cytarabine 300 mg/m2 IV, 1 dose on day 1

      Week 4:

      Dexamethasone§ 12 mg/m2/day PO, TID, Days 1 to 5

      Vincristine§ 2 mg/m2 IV(maximum 2mg), 1 dose on day 1

      Week 5*‡:

      etoposide 300 mg/m2 IV, 1 dose on day 1

      Cyclophosphamide 300 mg/m2 IV, 1 dose on day 1

      Week 6*:

      Methotrexate 40 mg/m2 IV, 1 dose on day 1

      6-mercaptopurine# 75 mg/m2 PO, QHS, Days 1 to 7

      Week 7*:

      teniposide 150 mg/m2 IV, 1 dose on day 1

      Cytarabine 300 mg/m2 IV, 1 dose on day 1

      Week 8*:

      Dexamethasone§ 12 mg/m2/day PO, TID, Days 1 to 5

      Vinblastine 6 mg/m2 IV(max 10 mg), 1 dose on day 1

      Plan for Stem Cell Transplant

      Patients who have positive MRD (high-risk or standard-risk) at the end of induction or all
      high-risk patients regardless of MRD are eligible for HSCT

        -  All high-risk patients are eligible for HSCT. HSCT will be performed as soon as MRD
           becomes negative after induction. If MRD becomes negative (&lt;0.01%) and a donor has not
           been found, the patient will continue chemotherapy phases (Consolidation I, Interim
           Continuation, etc) until a suitable donor is found.

        -  Those who have persistent positive MRD (&gt;0.01%) after Block C are also eligible for HSCT

      All standard-risk patients will continue chemotherapy if MRD is negative (&lt;0.01%) after
      induction.

        -  If MRD is positive (&gt;0.01%) after Block C of induction, they become eligible for HSCT.

        -  Standard-risk patients who have no response or progressive disease after Block A and who
           have positive MRD (&gt;0.01%) after Block B will be candidates for HSCT. They will be
           re-evaluated after Block C. If MRD after Block C is positive, follow the plan above. If
           MRD is negative after Block C, the management will be discussed with Transplant Service

      Contingency Plan

      Patients who do not achieve morphological CR (M1 marrow) after Induction

      If CR (M1 marrow) is not achieved after Induction, patients will proceed to Consolidation I.
      If they do not achieve CR after Consolidation I, they will be offered enrollment on the St.
      Jude NKHEM protocol or offered alternative therapy. If they do not achieve CR after NKHEM,
      they will come off treatment.

      Patients who achieve CR but have positive MRD (&gt;0.01%) after Block C of induction: Become
      eligible for HSCT. Up to two more courses of chemotherapy (course 1 and 2) will be given to
      attempt reducing MRD. They will receive HSCT as soon as MRD becomes negative (MRD may be
      repeated every 2-4 weeks as indicated).

      Standard-risk patients who have positive MRD (&gt;0.01%) after Block B will proceed to Block C.
      Patients in this category will become candidates for HSCT, but if MRD becomes negative after
      Block C, the management will be discussed with Transplant Service. Chemotherapy may be
      administered to reduce MRD prior to HSCT. Patients will be transplanted as soon as the MRD
      becomes negative.

      Patients (high-risk or standard-risk) who achieved CR, but have positive MRD (&gt;0.01%) after
      Block C of Induction will become eligible for HSCT. Up to two more courses of chemotherapy
      (course 1 and 2) will be given to attempt reducing MRD. They will receive HSCT as soon as MRD
      becomes negative. If MRD remains positive after course 2, then, they will proceed to HSCT
      after discussion with Transplant Service.

      Course 1

      Give chemotherapy according to the plan for Consolidation I. Start it immediately regardless
      of CBC. BMA will be performed when WBC &gt;1000/microL, ANC &gt;300/microL and platelets
      &gt;50,000/microL. If MRD is negative, they will receive HSCT.

      Course 2

      This course will be given if MRD is positive after Course 1. Patients will be offered
      enrollment on St. Jude NKHEM protocol.

      If they are still MRD positive after Course 2, patients may receive Interim Continuation,
      Consolidation II, and then Continuation until MRD becomes negative or while awaiting HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>End of re-induction Block C (approximately 1 month after the start of therapy)</time_frame>
    <description>The &quot;response rate&quot; is defined as the proportion of participants who attain morphological complete remission after the re-induction Block C, inclusive of all patients who begin re-induction. Morphological complete remission was defined as &lt;5% blasts in bone marrow by morphology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years after last patient completes therapy (approximately 4 years after enrollment)</time_frame>
    <description>OS is measured from the start of on-study to the date of death or to the last date of follow-up. Measurement is determined by Kaplan-Meyer estimate. The probability of survival at 5 years after diagnosis is given.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)</measure>
    <time_frame>End of Block Block C therapy (Day 46)</time_frame>
    <description>The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is &gt;=0.01%. The prevalence of MRD after Block C is defined as the proportion of MRD positives.</description>
  </other_outcome>
  <other_outcome>
    <measure>Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)</measure>
    <time_frame>End of Block B therapy (Day 19)</time_frame>
    <description>The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is &gt;=0.01%. The prevalence of MRD after Block B is defined as the proportion of MRD positives.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphoma, Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide, cytarabine, vincristine, dexamethasone</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>etoposide: VP-16, Vepesid(R)</other_name>
    <other_name>cytarabine: Ara-C, Cytosar-U(R)</other_name>
    <other_name>vincristine: Oncovin(R)</other_name>
    <other_name>dexamethasone: Decadron(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate, teniposide, PEG-asparaginase</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>methotrexate: MTX</other_name>
    <other_name>teniposide: VM-26, Vumon(R)</other_name>
    <other_name>PEG-asparaginase: Peg-L-Asparaginase, pegaspargase, Oncaspar(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>mitoxantrone: Novantrone(R)</other_name>
    <other_name>cyclophosphamide: Cytoxan(R)</other_name>
    <other_name>mercaptopurine: 6-MP, Purinethol(R)</other_name>
    <other_name>vinblastine: Velban(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase, erwinia asparaginase</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>L-asparaginase: Elspar(R)</other_name>
    <other_name>erwinia asparaginase: Erwinase(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy, intrathecal chemotherapy, steroid therapy</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplant</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Natural Killer (NK) Cell Transplant</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Childhood ALL in first relapse OR in first hematological relapse after an
             extramedullary relapse, OR not attaining a complete remission with frontline
             therapies, OR lymphoblastic leukemia in first relapse.

          -  Patients must be 21 years of age or younger

          -  Informed consent explained to and signed by parent/legal guardian.

        Exclusion Criteria

          -  Life expectancy less than 8 weeks

          -  Patients with mature B cell ALL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sima Jeha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>October 25, 2013</results_first_submitted>
  <results_first_submitted_qc>October 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2013</results_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoblastic</keyword>
  <keyword>Acute</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Teniposide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between May 2004 and August 2012, this study enrolled 47 participants with relapsed or refractory acute lymphoblastic leukemia (ALL): 40 were enrolled at St. Jude and 7 at Rady Children's Hospital.</recruitment_details>
      <pre_assignment_details>Seven participants were excluded from analysis: 6 who enrolled and received treatment prior to a therapy change in amendment 1.0 and one who was incorrectly enrolled on this study. Forty participants were included in the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Risk</title>
          <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
        </group>
        <group group_id="P2">
          <title>High Risk</title>
          <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient who was &gt;21 years at diagnosis was enrolled because early versions of the protocol had no upper age limit for participants previously treated on St Jude frontline protocols. The protocol was subsequently amended to change the age criteria to ≤21 years of age at diagnosis for all patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Risk</title>
          <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
        </group>
        <group group_id="B2">
          <title>High Risk</title>
          <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="5.0"/>
                    <measurement group_id="B2" value="11.3" spread="6.6"/>
                    <measurement group_id="B3" value="11.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" lower_limit="3.3" upper_limit="22.2"/>
                    <measurement group_id="B2" value="12" lower_limit="2.6" upper_limit="21.8"/>
                    <measurement group_id="B3" value="10" lower_limit="2.6" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>The &quot;response rate&quot; is defined as the proportion of participants who attain morphological complete remission after the re-induction Block C, inclusive of all patients who begin re-induction. Morphological complete remission was defined as &lt;5% blasts in bone marrow by morphology.</description>
        <time_frame>End of re-induction Block C (approximately 1 month after the start of therapy)</time_frame>
        <population>Response is defined as morphological complete remission after re-induction Block C. Participants who begin re-induction phase but fail to reach the end of Block C for whatever reason will be regarded as an induction failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Risk</title>
            <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
          </group>
          <group group_id="O2">
            <title>High Risk</title>
            <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The &quot;response rate&quot; is defined as the proportion of participants who attain morphological complete remission after the re-induction Block C, inclusive of all patients who begin re-induction. Morphological complete remission was defined as &lt;5% blasts in bone marrow by morphology.</description>
          <population>Response is defined as morphological complete remission after re-induction Block C. Participants who begin re-induction phase but fail to reach the end of Block C for whatever reason will be regarded as an induction failure.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.846"/>
                    <measurement group_id="O2" value="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure to reach complete remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154"/>
                    <measurement group_id="O2" value="0.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is measured from the start of on-study to the date of death or to the last date of follow-up. Measurement is determined by Kaplan-Meyer estimate. The probability of survival at 5 years after diagnosis is given.</description>
        <time_frame>2 years after last patient completes therapy (approximately 4 years after enrollment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Risk</title>
            <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
          </group>
          <group group_id="O2">
            <title>High Risk</title>
            <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is measured from the start of on-study to the date of death or to the last date of follow-up. Measurement is determined by Kaplan-Meyer estimate. The probability of survival at 5 years after diagnosis is given.</description>
          <units>probability</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" spread="0.103"/>
                    <measurement group_id="O2" value="0.357" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)</title>
        <description>The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is &gt;=0.01%. The prevalence of MRD after Block C is defined as the proportion of MRD positives.</description>
        <time_frame>End of Block Block C therapy (Day 46)</time_frame>
        <population>Protocol information for the comparison group of TOTXV Participants, including Participant Flow, Baseline Characteristics, and Adverse Events, is available on ClinicalTrials.gov under registration ID NCT00137111.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Risk</title>
            <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
          </group>
          <group group_id="O2">
            <title>High Risk</title>
            <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
          </group>
          <group group_id="O3">
            <title>TOTXV Participants</title>
            <description>Total therapy applies to all eligible patients and includes remission induction, consolidation, and continuation therapy. Participants received high-dose methotrexate infusion in upfront window treatment as described in NCT00137111.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)</title>
          <description>The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is &gt;=0.01%. The prevalence of MRD after Block C is defined as the proportion of MRD positives.</description>
          <population>Protocol information for the comparison group of TOTXV Participants, including Participant Flow, Baseline Characteristics, and Adverse Events, is available on ClinicalTrials.gov under registration ID NCT00137111.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="492"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative &lt;0.01%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive ≥0.01%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)</title>
        <description>The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is &gt;=0.01%. The prevalence of MRD after Block B is defined as the proportion of MRD positives.</description>
        <time_frame>End of Block B therapy (Day 19)</time_frame>
        <population>Protocol information for the comparison group of TOTXV Participants, including Participant Flow, Baseline Characteristics, and Adverse Events, is available on ClinicalTrials.gov under registration ID NCT00137111.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Risk</title>
            <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
          </group>
          <group group_id="O2">
            <title>High Risk</title>
            <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
          </group>
          <group group_id="O3">
            <title>TOTXV Participants</title>
            <description>Total therapy applies to all eligible patients and includes remission induction, consolidation, and continuation therapy. Participants received high-dose methotrexate infusion in upfront window treatment as described in NCT00137111.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)</title>
          <description>The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is &gt;=0.01%. The prevalence of MRD after Block B is defined as the proportion of MRD positives.</description>
          <population>Protocol information for the comparison group of TOTXV Participants, including Participant Flow, Baseline Characteristics, and Adverse Events, is available on ClinicalTrials.gov under registration ID NCT00137111.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative &lt;0.01%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive ≥0.01%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time a participant began therapy through 30 days after completion of protocol therapy.</time_frame>
      <desc>The Other Adverse Events section includes reports of events, Grades 1 through 5.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Risk</title>
          <description>Participants with isolated extramedullary relapse (with blasts in bone marrow (BM) &lt;5%) regardless of the timing of relapse, and participants with B-lineage ALL who develop a late hematological relapse (isolated BM or combined).</description>
        </group>
        <group group_id="E2">
          <title>High Risk</title>
          <description>Participants with T-cell ALL who develop a hematological [isolated bone marrow (BM) or combined] relapse, irrespective of length of initial remission, participants with B-lineage ALL who develop early hematological relapse (isolated BM or combined), and participants relapsing after hematopoietic stem cell transplantation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia, supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia, ventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, blood</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, brain (encephalitis, infectious)</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, Catheter-related</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Neuroendocrine: ADH secretion abnormality (e.g., SIADH or low ADH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam), oral cavity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Typhlitis (cecal inflammation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>In the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain, neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain, extremity-limb</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain, abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain, head/headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, blood</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, sinus</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, catheter-related</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, upper airway NOS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, lung (pneumonia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, upper airway NOS</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, skin (cellulitis)</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, skin (cellulitis)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, pharynx</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, lung (pneumonia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, lip/perioral</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection, wound</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy, motor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neuropathy, sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sima Jeha, MD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>866-278-5833</phone>
      <email>info@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

